The endogenous HDAC1 inhibitor protein maspin (mammary serine protease inhibitor), which was induced by the HDAC inhibitor entinostat, suppressed AR expression in prostate cancers and led to sensitization of androgen-sensitive LNCaP and castration-resistant 22Rv1 prostate cancer cells to enzalutamide treatment[39]. This evidence concerns the gene HDAC1 and prostate carcinoma.